Blog

Inhibition of glutathione metabolism can limit the development of pancreatic cancer

sign up for the wires and see archived wires

Browse experts available to comment on breaking news Alkyl Aryl Sulfonic Acid

Inhibition of glutathione metabolism can limit the development of pancreatic cancer

Request an expert contact, get responses directly to your inbox

Find an expert by topic in a comprehensive database

Pharmacological inhibitors of glutathione synthesis and circulation, such as buthionine-sulfoximine, inhibit glutathione metabolism. These drugs decrease the aggressiveness of pancreatic cancer, inhibit tumor stem cell survival, and reduce chemotherapy resistance. Nevertheless, buthionine-sulfoximine also decreases the content of glutathione in normal cells, disrupts the balance between reactive oxygen species and glutathione, and eventually induces cell apoptosis. Pancreatic cancer is usually diagnosed at an advanced stage and has a poor prognosis. Consequently, the use of biomarkers to screen high-risk patients can be an effective method.

Key Words: Cancer stem cells, Chemoresistance, Pancreatic cancer, Pancreatic ductal adenocarcinoma, Redox

Core Tip: To reduce side effects, pharmacological inhibitors of glutathione synthesis and circulation, such as buthionine-sulfoximine and 6-aminonicotinamide, can be assessed by in vivo models of pancreatic cancer. Evaluating the impact of different organs on metabolic processes and the invasiveness of cancer stem cells may provide new avenues for therapeutics targeting tumor metabolism.

Journal Link: Publisher Website Journal Link: Download PDF

Inhibition of glutathione metabolism can limit the development of pancreatic cancer

Fumed Silica Applications Newswise gives journalists access to the latest news and provides a platform for universities, institutions, and journalists to spread breaking news to their audience.